Results 121 to 130 of about 213,106 (383)
Biomarkers of lung congestion and injury in acute heart failure
ESC Heart Failure, Volume 12, Issue 2, Page 781-789, April 2025.Abstract Acute heart failure (AHF) classification and management are primarily based on lung congestion and/or hypoperfusion. The quantification of the vascular and tissue lung damage is not standard practice though biomarkers of lung injury may play a relevant role in this context.
Marco Guazzi +9 more
wiley +1 more source
The integration of BNP and NT-proBNP into clinical medicine
Swiss Medical Weekly, 2007 B-type natriuretic peptide (BNP) and NTproBNP have been shown to be extremely helpful in the diagnosis and management of patients with heart failure (HF). These neurohormones are predominately secreted from the left and the right cardiac ventricle in response to volume and pressure overload.
Christian, Mueller +4 more
openaire +3 more sources
The effects of short-term omission of daily medication on the pathophysiology of heart failure [PDF]
, 2016 Aims Pharmacological therapies for heart failure (HF) aim to improve congestion, symptoms, and prognosis. Failing to take medication is a potential cause of worsening HF.
Abraham +31 more
core +4 more sources
MELD score predicts outcomes in patients with advanced heart failure: A longitudinal evaluation
ESC Heart Failure, Volume 12, Issue 2, Page 839-847, April 2025.Abstract Aims Advanced heart failure (AHF) is characterized by recurrent episodes of haemodynamic instability and frequent hospitalizations, leading to a progressive decline in quality of life and high mortality rates. The objectives of this study were to evaluate the effect of the model for end‐stage liver disease (MELD) score and its variations in ...
Francesco Curcio +10 more
wiley +1 more source
ESC Heart Failure, Volume 12, Issue 2, Page 955-967, April 2025.Abstract Wild‐type transthyretin amyloid cardiomyopathy (ATTRwt‐CM) is a progressive and infiltrative cardiac disorder that may cause fatal consequences if left untreated. The estimated survival time from diagnosis is approximately 3–6 years. Because of the non‐specificity of initial symptom manifestation and insufficient awareness among treating ...
Yasuhiro Izumiya +9 more
wiley +1 more source
Clinical Research in Cardiology, 2019 Background In heart failure (HF), levels of NT-proBNP are influenced by the presence of concomitant atrial fibrillation (AF), making it difficult to distinguish between HF versus AF in patients with raised NT-proBNP.
B. Santema +23 more
semanticscholar +1 more source
Individual variability in cardiac biomarker release after 30 min of high-intensity rowing in elite and amateur athletes [PDF]
, 2015 This study had two objectives: (i) to examine individual variation in the pattern of cardiac troponin I (cTnI) and N-terminal pro-brain natriuretic peptide (NT-proBNP) release in response to high-intensity rowing exercise, and (ii) to establish whether ...
Alejandro Legaz-Arrese +16 more
core +1 more source
ESC Heart Failure, Volume 12, Issue 2, Page 848-858, April 2025.Abstract Aims Blood levels of N‐terminal pro‐brain natriuretic peptide (NT‐proBNP) may be modified by low renal clearance and anaemia. The aim of this study was to investigate the impact of the blood NT‐proBNP level on cardiovascular and renal outcomes in patients with these two manifestations.
Hiroshi Nishi +4 more
wiley +1 more source
Impact of an endurance training program on exercise-induced cardiac biomarker release [PDF]
, 2015 We evaluated the influence of a 14-wk endurance running program on the exercise-induced release of high-sensitivity cardiac troponin T (hs-cTnT) and NH2-terminal pro-brain natriuretic peptide (NT-proBNP).
Alejandro Legaz-Arrese +14 more
core +2 more sources
ESC Heart Failure, Volume 12, Issue 2, Page 859-868, April 2025.Abstract Aims Natriuretic peptide‐based pre‐heart failure screening has been proposed in recent guidelines. However, an effective strategy to identify screening targets from the general population, more than half of which are at risk for heart failure or pre‐heart failure, has not been well established.
Yuichiro Mori +5 more
wiley +1 more source